Shaida don kuma magance Rigakafin Lafiya tare da Statins
Binciken farko ya haifar da jin dadi a cikin rikici game da yiwuwar haɗi tsakanin magungunan ƙwayoyin cholesterol wanda aka sani da kwayoyi da kuma rigakafin lalata . Amma bayanan binciken ba su samo irin wannan ƙaddara ba.
Binciken Lancet yana nuna rashin haɗari
A watan Nuwambar 2000, binciken da aka wallafa a Lancet ya gano cewa mutane fiye da shekaru 50 da aka tsara sunadaran sunadaran hadarin ci gaba .
Masu bincike sun kwatanta da mutane 284 da suke da lalata ("cases") tare da 1,080 "iko" wanda bai yi ba. Irin wannan nazarin ana san shi a matsayin nazari na rikitarwa. Wa] annan wa] anda aka tsara su, sun kasance da mummunar haɗari, idan aka kwatanta da wa] anda ba a ba su ka'ida ba, ko da bayan da aka ha] a da irin wa] anda ke da shekaru, jinsi, da tarihin cututtukan zuciya. Sakamakon ya kasance da muhimmanci sosai.
Ƙarin Nazarin Yarda La'akari da Ka'idojin Labaran Lafiyar da Rigakafi
Ko da yake binciken na biyu da aka wallafa a 2004 ya gano cewa masu amfani da labaran sun kasance sun kamu da cutar Alzheimer a cikin kashi 39 cikin 100 idan aka kwatanta da masu amfani da statin, wannan ma ya kasance binciken bincike. Don haka waɗannan karatun biyu sun nuna cewa kwayoyin sun rage hadarin cutar Alzheimer? Abin takaici ba.
Cochrane Database of Reviews Systematic ya nuna muhimmancin babban binciken da aka gudanar game da yin amfani da statins a cikin mutanen da ke fuskantar haɗarin Alzheimer da sauran lalacewar, ciki har da mutane 26,340.
Wadannan sune masu gwagwarmayar maganin wuri-wuri guda biyu, wanda shine mafi mahimmanci irin binciken. Saboda binciken bincike-rikodin ya sake dubawa a lokaci kuma ba a bazu ba, maƙasudin da za a iya samo daga gare su an iyakance ne. Makarantun makafi biyu suna sa idanu a lokaci, an tsara su domin masu binciken binciken basu san abin da marasa lafiya ke yin maganin miyagun ƙwayoyi da kuma wadanda suke samun wuri kuma sun fi dacewa wajen nuna hanyar da tasiri.
Magunguna a cikin binciken farko na makafi guda biyu sun biyo bayan kimanin shekaru 3.2, kuma waɗanda ke cikin binciken na biyu na shekaru biyar. Ayyukan tunani na mutane a binciken farko sun ki yarda da haka. Kuma a cikin binciken na biyu, babu wani bambanci game da rikice-rikicen lalata tsakanin batutuwa da suka sami statin tare da waɗanda suka sami wuribo.
Bisa ga ƙarfin wadannan karatun baya, shaidun da za su tabbatar cewa ka'idodi sun hana Alzheimer ko wasu ƙaddamar da shi a wannan lokaci.
Sources:
Ƙungiyar Cochrane na Kamfanin Bayani na Gano. 2016 Janairu 1: Statins for Prevention of Dementia. http://www.ncbi.nlm.nih.gov/pubmed/26727124.
Jick H, MD, Zornberg GL, MD, Jick SS, DSc, Seshadri S, MD, Drachman DA, MD. "Statins da kuma Hadarin Dementia." A Lancet 2000 vol. 356, Issue 9242: 1627-31.
McGuinness B, Craig D, Bullock R, Passmore P. "Statins for Prevention of Dementia". Cochrane Database of Review System 2009, Issue 2.
Zamrini E, McGwin G, Roseman J. "Ƙungiyar Tsakanin Amfani da Statin da Alzheimer's Disease". Neuroepidemiology 2004; 23: 94-98.
-Edited by Esther Heerema, MSW